<DOC>
	<DOCNO>NCT01044069</DOCNO>
	<brief_summary>This study investigational approach use immune cell , call `` T cell '' , kill leukemia . These T cell remove blood , modify laboratory , put back body . T cell fight infection also kill cancer cell case . However , right T cell unable kill cancer cell . For reason put one gene T cell allow recognize kill leukemia cell . This gene put T cell weaken virus . The gene produce protein T cell help T cell recognize leukemia cell possibly kill . The doctor find T cell modify way cure ALL-like cancer mouse . The main goal study determine safety appropriate dose modify T cell patient ALL . This do `` clinical trial . '' The dose modified T-cells depend disease present bone marrow . The patient also receive chemotherapy T cell . We use normally chemotherapy use patient leukemia . The chemotherapy give reduce leukemia allow T cell live long .</brief_summary>
	<brief_title>Precursor B Cell Acute Lymphoblastic Leukemia ( B-ALL ) Treated With Autologous T Cells Genetically Targeted B Cell Specific Antigen CD19</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Adult patient eligible ( &gt; = 18 year old ) . Patients must B ALL refractory , relapse , MRD , first CR described . Complete remission define restoration normal hematopoiesis neutrophil count &gt; 1,000 x 106/L , platelet count &gt; 100,000 x 106/L , hemoglobin &gt; 10 g/dL . Blasts &lt; 5 % posttreatment bone marrow differential . Furthermore , clinical evidence leukemia minimum four week . MRD define patient meet criterion CR , residual disease measure quantitative PCR , flow deepsequencing IgH rearrangement . The assay blood and/or bone marrow define MRD qPCR cycle threshold ( CT ) least 1 CT value &lt; low CT value background . Outside laboratory test may suffice assessment discretion Principal Investigator . Relapsed BALL define patient meet criterion CR develop recurrent disease ( increase bone marrow blast ) . Refractory patient define patient achieve CR 1 cycle induction chemotherapy Patients must diagnosis BALL flow cytometry , bone marrow histology , and/or cytogenetics . Patients must CD19+ ALL confirm flow cytometry and/or immunohistochemistry . Creatinine &lt; 2.0 mg/100 ml , bilirubin &lt; 2.0 mg/100 ml , AST ALT &lt; 3x normal , PT PTT &lt; 2x normal outside set stable chronic anticoagulation therapy . LFTs ( Bilirubin , AST , and/or ALT ) may acceptable elevation secondary leukemia infiltration leukemia therapy tyrosine kinase inhibitor . Adequate cardiac function ( LVEF ≥ 40 % ) assess ECHO MUGA similar cardiac imaging perform within 1 month enrollment . Adequate pulmonary function assess ≥ 92 % oxygen saturation room air pulse oximetry . Patients must adequate access leukapheresis procedure assess staff MSKCC Donor Room . Life expectancy &gt; 3 month Karnofsky performance status &lt; 70 . Active central nervous system ( CNS ) leukemia , define unequivocal morphologic evidence lymphoblast cerebrospinal fluid ( CSF ) symptomatic CNS leukemia ( i.e . cranial nerve palsy significant neurologic dysfunction ) within 28 day enrollment . Prophylactic intrathecal medication reason exclusion . Patients previously treat allogeneic SCT currently complicate active GVHD require T cell suppressive therapy . Patients follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Myocardial infarction ≤6 month prior enrollment History clinically significant ventricular arrhythmia unexplained syncope , believe vasovagal nature due dehydration History severe nonischemic cardiomyopathy EF ≤20 % Patients HIV , hepatitis B hepatitis C infection . Patients concurrent active malignancy define malignancy require therapy expectant observation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>T cell</keyword>
	<keyword>leukapheresis</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>09-114</keyword>
</DOC>